$66.74 +0.04 (0.06%) Seattle Genetics Inc - NASDAQ

Dec. 5, 2016 | 11:25 AM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 66.74
Trade Time: Dec 05 11:25 AM Eastern Daylight Time
Change: +0.04 (0.06%)
Prev Close: 66.70
Open: 68.16
Bid: 66.65
Ask: 66.78
  1. No results found.
  1. Biotechs Aerie, Medicines Co., Tesaro Could Rocket, Or Be Bought: RBC

    Investors Business Daily | Dec. 1, 2016 | 14:14PM EST
  2. Alert: Alzheimer’s Drug Fails In Clinical Trial - Stocks Sink

    TalkMarkets | Nov. 24, 2016 | 00:03AM EST
  3. Rayno Biobeat #4: Sector Shift Underway But What’s Next For Biotech?

    TalkMarkets | Nov. 23, 2016 | 00:13AM EST
  4. Rayno Biobeat #3…Trump Biotech Rally Leads Market Up

    TalkMarkets | Nov. 9, 2016 | 23:23PM EST
  5. Biotech Meltdown: Financial Metrics Offer Few Clues For What is Next

    TalkMarkets | Nov. 1, 2016 | 06:52AM EST
  6. Seattle Genetics (SGEN) Loss Narrower Than Expected In Q3

    TalkMarkets | Oct. 29, 2016 | 19:13PM EST
  7. Comparing Actinium's Actimab-A To Seattle Genetics' SGN-CD33A

    TalkMarkets | Oct. 11, 2016 | 17:40PM EST
  8. Apple Upgraded; Twitter A 'Loser'; Caterpillar Price Target Hiked

    Investors Business Daily | Jul. 27, 2016 | 08:25AM EST
  9. Benzinga's Top Upgrades

    Benzinga | Feb. 10, 2016 | 08:55AM EST
  10. Benzinga's Top Initiations

    Benzinga | Feb. 4, 2016 | 09:56AM EST
  11. 4 Stocks Moving On Breast-Cancer News

    IBD | Dec. 10, 2015 | 16:04PM EST
  12. Seattle Genetics Highlights Data from SGN-CD19A Antibody-Drug Conjugate Program at #ASH2015

    Benzinga | Dec. 6, 2015 | 08:42AM EST
  13. Benzinga's Top Upgrades

    Benzinga | Oct. 30, 2015 | 08:10AM EST
  14. Here's Why Biotechs Fell On Monday

    Benzinga | Oct. 19, 2015 | 15:29PM EST
  15. Seattle Genetics Initiates Phase 2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) Combination Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

    Benzinga | Oct. 19, 2015 | 07:00AM EST
Trading Center